AstraZeneca Reportedly Cuts About 600 US Sales Roles to Fund Its Pipeline

what happened

Bloomberg, cited by Stocktwits, reports that AstraZeneca has removed about 600 positions from its US sales teams covering respiratory and immunology medicines. The layoffs reached staff who promote the asthma treatments Breztri and Airsupra. The company is treating the move as an early step in a three-year cost program. Some affected workers may be moved into other roles within the company, which employs more than 25,000 people in the US. The drugmaker also reportedly reduced its agreement with Syneos Health, a firm that helps market its products in America.

At the time of writing the stock was roughly unchanged, having climbed as high as 1% before slipping 0.2% briefly. Sales in the respiratory and immunology portfolio reached $7.3 billion in the first nine months of 2026, or 16% of group revenue, rising 10% at constant exchange rates according to third-quarter results.

why it matters

The program targets up to $2 billion in one-time restructuring costs and $1.5 billion in annualized pre-tax savings by the end of 2029, with most of the savings reinvested in the pipeline. Investors are weighing these steps against patent losses on older drugs such as Farxiga and Brilinta, and against a string of deals this year, including a licensing pact with CSPC worth up to about $18.5 billion and a reported roughly $10 billion move for Rhythm Pharmaceuticals.

market impact

AZN: cost cuts and redirected funds toward the pipeline keep the focus on spending and new drugs

tags

instruments